Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children
- PMID: 22520945
- PMCID: PMC5780728
- DOI: 10.1111/j.1750-2659.2012.00367.x
Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children
Abstract
In an open-label study, 49 children aged 1-12 years received oseltamivir (30-75 mg once daily depending on bodyweight) for 6 weeks for influenza prophylaxis. Seventeen participants reported 22 adverse events (AEs); in three participants, AEs were considered probably drug related (nausea or vomiting). No serious AEs were reported. The tolerability profile was similar to pooled safety data from treatment studies (duration of 5 days) in children.
Trial registration: ClinicalTrials.gov NCT00412555.
© 2012 Blackwell Publishing Ltd.
References
-
- Heikkinen T. Influenza in children. Acta Paediatr 2006; 95:778–784. - PubMed
-
- Hurwitz ES, Haber M, Chang A et al. Studies of the 1996–1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 2000; 182:1218–1221. - PubMed
-
- Heikkinen T, Silvennoinen H, Peltola V et al. Burden of influenza in children in the community. J Infect Dis 2004; 190:1369–1373. - PubMed
-
- Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003; 36:299–305. - PubMed
-
- Lahti E, Peltola V, Virkki R, Ruuskanen O. Influenza pneumonia. Pediatr Infect Dis J 2006; 25:160–164. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical